Skip to main content

RSV vaccine from GSK shows potential to protect adults 50 to 59

The results suggest that GSK's shot could help protect a wider population from RSV, which causes thousands of hospitalizations and deaths each year.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.